Atai Life Sciences N.V.
ATAI
$4.79
$0.2154.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 719.00K | 1.56M | -5.00K | 40.00K | 273.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 719.00K | 1.56M | -5.00K | 40.00K | 273.00K |
| Cost of Revenue | -- | 10.84M | -- | -- | -- |
| Gross Profit | 719.00K | -9.28M | -5.00K | 40.00K | 273.00K |
| SG&A Expenses | 14.90M | 9.99M | 11.44M | 10.27M | 13.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.99M | 20.83M | 29.34M | 22.64M | 26.00M |
| Operating Income | -25.27M | -19.27M | -29.35M | -22.60M | -25.73M |
| Income Before Tax | -27.68M | -26.34M | -39.71M | -26.49M | -57.73M |
| Income Tax Expenses | 65.00K | 128.00K | -718.00K | -178.00K | -362.00K |
| Earnings from Continuing Operations | -27.75M | -26.47M | -38.99M | -26.31M | -57.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 17.00K | 34.00K | 33.00K | 25.00K | 57.00K |
| Net Income | -27.73M | -26.43M | -38.96M | -26.29M | -57.31M |
| EBIT | -25.27M | -19.27M | -29.35M | -22.60M | -25.73M |
| EBITDA | -25.05M | -19.05M | -29.12M | -22.52M | -25.65M |
| EPS Basic | -0.14 | -0.15 | -0.24 | -0.16 | -0.36 |
| Normalized Basic EPS | -0.10 | -0.12 | -0.12 | -0.11 | -0.22 |
| EPS Diluted | -0.14 | -0.15 | -0.24 | -0.16 | -0.36 |
| Normalized Diluted EPS | -0.10 | -0.12 | -0.12 | -0.11 | -0.22 |
| Average Basic Shares Outstanding | 196.56M | 176.27M | 160.71M | 160.62M | 160.39M |
| Average Diluted Shares Outstanding | 196.56M | 176.27M | 160.71M | 160.62M | 160.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |